<?xml version="1.0" encoding="UTF-8"?>
<p>The treatment of IBD has been revolutionized over the past decade with the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection becomes a key safety concern in patients with IBD [
 <xref rid="b1-ir-2019-09155" ref-type="bibr">1</xref>]. In particular, the course of viral hepatitis is determined by the interaction between the virus and the hostâ€™s immunity. If immunity is compromised by immunosuppression, the risk of reactivation increases, and HBV reactivations in immunosuppressed patients have been associated with hepatic decompensation in a considerable proportion of cases [
 <xref rid="b2-ir-2019-09155" ref-type="bibr">2</xref>,
 <xref rid="b3-ir-2019-09155" ref-type="bibr">3</xref>]. Thus, risk assessment for viral hepatitis is one of the important quality process indicators for the management of IBD patients [
 <xref rid="b4-ir-2019-09155" ref-type="bibr">4</xref>].
</p>
